National Gynecologic Oncology Fellows Forum

Wednesday, April 2, 2025

4:00 PM – 6:00 PM

Registration Open

6:00 pm – 7:30 pm

Welcome Reception

Thursday, April 3, 2025

7:00 AM – 8:00 AM

Breakfast & Registration

8:00 AM -9:55 AM

General Session 1

• Welcome & Opening Remarks
• Adapting to a New Era: The SHAPE Trial and Its potential Effect on Surgical Management and Fellow Education in Cervical Cancer, Chelsea Stewart, MD, University of Tennessee Health Science Center
• Mapping Shared Neoantigens and T cell Dysregulation in MSI-H Endometrial Cancer Patients, Sharonne Holtzman, MD, Icahn School of Medicine at The Mount Sinai Hospital
• Higher socioeconomic status does not improve endometrial cancer survival for Black women in the United States, Larissa Weirich, MD, Emory University
• Spatial genomic analysis of MLH1 hypermethylated and Lynch syndrome endometrial cancers reveals key differences in the tumor immune microenvironment, Sagar Chokshi, MD, University of South Alabama Mitchell Cancer Institute
• Discussion/Audience Q&A
• Association of Artificial Intelligence-based Analysis of Body Composition and Surgical Outcomes in Gynecologic Cancers, Luxue Deng, MD, Roswell Park Comprehensive Cancer Center
• How Are We Caring for the Oldest Ovarian Cancer Patients? Evaluating Post EWOC-1 Adaptations and Oncologic Decision-Making, Jude Nawlo, MD, New York University
• Rest Assured: High Preoperative Sleep Efficiency Reduces Postoperative Complications and Opioid Prescriptions in Patients Undergoing Surgeries with Gynecologic Oncologists, Connor Wang, MD, Northwestern University Feinberg School of Medicine
• Sentinel lymph node mapping in women with endometrial cancer with a preoperative diagnosis of complex atypical endometrial hyperplasia, Divya Gowthaman, MD, Northwell Gynecologic Oncology
• Discussion/Audience Q&A

9:55 AM – 10:25 AM

Coffee Break

10:25 AM – 10:55 AM

Faculty Lecture

• Trial Design/Basic Stats, Mario Leitao, MD, Memorial Sloan Kettering Cancer Center

10:55 AM – 12:30 PM

General Session 2

• Concordance and frequency of TP53 protein expression and gene sequence in mismatch repair proficient (pMMR) and POLE wild-type endometrial cancer: An Endometrial Cancer Molecularly Targeted Therapy Consortium database study, Nujsaubnusi Vue, MD, Allegheny Health Network
• Postoperative complications in gynecologic oncology patients receiving therapeutic anticoagulation, Hannah McLaughlin, MD, University of Michigan
• Improvements and Disparities in Survival for High-Grade Serous Ovarian Cancer: A Contemporary Assessment of Real-World Patients, Ahmed Hussain, MD, Walter Reed National Military Medical Center
• Rare Ovarian Adenocarcinomas Exhibit a Distinct Germline Landscape, Corbyn Nchako, MD, Memorial Sloan Kettering Cancer Center
• Discussion
• Onvansertib in combination with carboplatin demonstrates enhanced anti-tumorigenic effects in pre-clinical models of serous endometrial cancer, Glenn Boyles, MD, University of North Carolina
• Adjuvant Chemotherapy Does Not Appear to Improve Survival in Patients with 2009 FIGO Stage I Uterine Serous Carcinoma without Myoinvasion, Stephen Graves, MD, Memorial Sloan Kettering Cancer Center
• Pembrolizumab plus lenvatinib in women with advanced or recurrent uterine carcinosarcoma, Qi Zhang, MD, Atrium Levine Cancer Institute
• Discussion

12:30 PM – 2:00 PM

Group Luncheon

• Invited Speaker, Dr. Ronald Alvarez

2:30 PM – 5:30 PM:

Team Building Event on the Beach

6:00 PM – 9:00 PM:

Margaritaville Dinner

Friday, April 4, 2025

7:00 AM – 8:00 AM

Breakfast & Registration Help Desk

8:00 AM – 10:00 AM

General Session 3

• Welcome & Opening Remarks
• Examining Activin A Expression as a Biomarker in Platinum-Sensitive and Platinum-Refractory High-Grade Serous Ovarian Cancer, Emily O’Brien, MD, University of Alabama at Birmingham
• Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine serous carcinoma, Michelle Greenman, MD, Yale University School of Medicine
• Predictors of treatment delay and prolongation in locally advanced cervical cancer, Maya Gross, MD, University of Washington
• The Impact of Microbial Driven Inflammation on Cervical Cancer Cells, Ann Mercier, MD, Icahn School of Medicine at Mt Sinai Hospital
• Discussion
• Utility of Preoperative Imaging in Endometrial Carcinoma, Clarissa Lam, MD, Memorial Sloan Kettering Cancer Center
• Ultrasonography based measurements of endometrial thickness in patients with p53 abnormal endometrial carcinomas, Rachel Mojdehbakhsh, MD, University of Wisconsin
• Clinically node-positive cervical cancer: does surgery have a role?,  Jenna Zimmerman, MD, Allegheny Health Network
• The effectiveness of low-pressure pneumoperitoneum on post-operative outcomes in gynecologic oncology surgery, Vasanti Jhaveri, MD, St. Luke’s University Health Network
• Discussion

10:00 AM – 10:30 AM

Faculty Lecture

• Time Management, Christine Walsh, MD, University of Colorado – Anschutz Medical Campus

10:30 AM – 11:00 AM

Coffee Break

11:00 AM – 12:40 PM

General Session 4

• Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis), Katherine Baumann, MD, Beth Israel Deaconess Medical Center
• Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers, Julia Salinaro, MD, Program in Women’s Oncology, Women and Infant’s Hospital, Brown University
• Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes, Vinita Popat, MD, City of Hope
• Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity in Gynecologic Cancer Care, Rita Sartor, MD, Penn Medicine
• Discussion
• The impact of Janus kinase 1 (JAK1) mutations and major histocompatibility complex class I (MHC-I) expression on response to immune checkpoint inhibition in endometrial cancer, Erica Carballo, MD, Vanderbilt University Medical Center
• Clinicopathologic features and survival outcomes in women with uterine versus retroperitoneal leiomyosarcoma, Christina Curtin, MD, Memorial Sloan Kettering Cancer Center
• Use of Mirvetuximab Soravtansine-Gynx in Combination with Bevacizumab is Associated with a Higher Progression-Free Survival, Jill Roberts, MD, University of Miami Hospital/Sylvester Cancer Center
• Discussion & Day 2 Remarks

12:40 PM – 1:40 PM

Group Luncheon

Afternoon

Free Time

7:00 PM – 9:00 PM

Group Dinner

Saturday, April 5, 2025

8:00 AM – 9:00 AM

Breakfast & Registration Help Desk

9:00 AM – 10:45 AM

General Session 5

• Welcome & Opening Remarks
• The decline of radical hysterectomies performed by gynecologic oncologists in the United States: 2004-2020, Alicia Youssef, MD, MGH
• Variables impacting prolonged post-anesthesia care unit length of stay in gynecologic cancer patients in the era of same day minimally invasive hysterectomy, Sarah Bell, MD, UPMC
• Correlation between the administration of SARS-CoV-2 vaccinations and infusion-related hypersensitivity reactions with taxane administration in patients with gynecologic malignancies, Bethany Werner, MD, The University of Oklahoma Health Sciences Center
• Disparities in immunotherapy use for primary treatment of advanced cervical cancer prior to Federal Drug and Administration approval: a National Cancer Database study (2014-2021), Patrick Penalosa, MD, UC San Diego Health, Moores Cancer Center
• Discussion
• De-escalation of Radiation Therapy in Advanced Endometrial Cancer: Analysis of the National Cancer Database, Judy Hayek, MD, Maimonides/SUNY Downstate HSU
• Resistance mechanisms of FOLR1 antibody–drug conjugate therapy in recurrent high-grade serous ovarian cancer, Matthew Flint, MD, Memorial Sloan Kettering Cancer Center
• The utility of circulating tumor DNA for detecting recurrence during surveillance in patients with high-risk uterine cancer, Allison Walker, MD, St. Luke’s University Health Network
• Discussion

10:45 AM – 11:00 AM

Coffee Break

11:00 AM – 11:30 AM

Faculty Lecture

• Publishing, Susan Modesitt, MD, Winship Cancer Institute of Emory University

11:30 AM – 12:40 PM

General Session 6

• NSC59984 is a potent radiosensitizer and cytotoxic agent in in vitro and in vivo models of TP53mut endometrial cancer, Camilla Yu, MD, Cleveland Clinic Foundation
• Identification of Quorum Sensing Meolecules in Endometrial Cancer: Exploring Vaginal Microbiome Interactions as a Risk Biomarker, Ana Rosario Santos, MD, University of Miami/Jackson Health System
• A Lower Rate of Homologous Recombination Deficiency in Epithelial Ovarian Cancer Patients in the Mid-South, Anya Laibangyang, MD, University of Tennessee Health Science Center
• Homologous recombination (HR) status influences response to hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of interval debulking surgery (IDS) for ovarian cancer, Khrystyna Levytska, MD, Cedars-Sinai Medical Center
• Cross-Language Insights: Comparing Spanish and English-Language Cervical Cancer Content on TikTok, Jessica Velasquez, MD, The Ohio State University Wexner Medical Center
• Discussion

12:40 PM – 1:00 PM

Faculty Lecture

• What is The GOG Foundation?, Thomas Herzog, MD, University of Cincinnati

1:00 PM – 2:30 PM

Awards Celebration Luncheon

Registration & Housing information will be included in the Abstract Submission Acceptance letters and Sponsorship Confirmation details.

For more information, please contact jcummins@gog.org.

Thank you for your interest in the National Gynecologic Oncology Fellows Forum.

On behalf of the physician faculty for the National Gynecologic Oncology Fellows Forum, we are thrilled to share the exciting news about our latest initiative, the National Gynecologic Oncology Fellows Forum. This dynamic program is designed to cultivate the next generation of young investigators.

The National Gynecologic Oncology Fellows Forum represents a vital initiative dedicated to developing the key skills that emerging researchers require: leadership, effective communication, and meaningful engagement. Our mission is to provide these promising young scholars with the resources necessary to excel in their professional journeys and advance clinical research in our field. By offering targeted sessions, interactive experiences and tailored mentorship, the forum aims to empower fellows to enhance their skills and make an impactful contribution in their gynecologic oncology career.

We believe that with your support, we can make a profound impact on the future of gynecology oncology by empowering these talented individuals to reach their full potential. We look forward to the possibility of inviting you to participate at this important endeavor and would be delighted to discuss how you can play a role in shaping the future of our field.

Thank you for considering this opportunity to support the next generation of leaders in gynecologic oncology.

Click here to download the Sponsorship Prospectus.

Please contact Jenna Cummins at jcummins@gog.org for additional information.

THANK YOU SPONSORS

The National Gynecologic Oncology Fellows Forum is grateful for our 2025 Annual Meeting Commercial Supporters.

Pfizer Oncology | Genmab

Company Website

Our Purpose: We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today.

AbbVie

Company Website

AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people’s lives.

AstraZeneca

Company Website

We are transforming the future of healthcare by unlocking the power of what science can do, for people, society and planet.